For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?
Patients with acute respiratory failure require mechanical ventilation to help them breathe until they recover from their acute illness. Although mechanical ventilation is necessary to sustain life in such situations, it can induce weakness of the respiratory muscles which may lead to prolonged dependence on the ventilator. Prolonged dependence on mechanical ventilation is associated with increased mortality, morbidity and costs to the healthcare system. Thus, a main goal of assisted mechanical ventilation is to reduce the patient's respiratory distress while maintaining some respiratory muscle activity. To attain this goal, the amount of ventilator assistance should theoretically be adjusted to target normal or reasonable levels of respiratory effort. Modes of Mechanical Ventilation: Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mode of mechanical ventilation which delivers assistance to breathe in proportion to the patient's effort. The proportional assistance, called the gain, can be adjusted by the clinician to maintain the patient's respiratory effort or workload within a reasonable range. This is the only mode of ventilation which allows for measurement and targeting of a specific range of respiratory muscle activity by the patient. Pressure support ventilation (PSV) is a mode of ventilation which is considered the current standard of care for assisting breathing of patients during the recovery phase of acute respiratory failure. Several studies have shown short term advantages of PAV over PSV, including improved patient-ventilator synchronization, improved adaptability to changes in patient effort, and improved sleep quality. Goal of this Randomized Controlled Trial: To demonstrate that for patients with acute respiratory failure, ventilation with PAV+, being more physiological, will result in a shorter duration of time spent on mechanical ventilation than ventilation with PSV.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
El Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"
Buenos Aires, Argentina
Time from randomization to successful liberation from invasive mechanical ventilation.
"Successful liberation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Time frame: up to 90 days
Ventilator-free days at 14, 21 and 28 days post randomization
"Ventilator-free days" (VFDs) are defined as the number of days alive and free of INVASIVE ventilation post SUCCESSFUL EXTUBATION or post successful termination of invasive mechanical ventilation (MV) from time of randomization to day 21 post randomization. "Successful extubation" is defined as removal of the endotracheal tube AND remaining alive with no need for reintubation/reinstitution of invasive mechanical ventilation for 7 days post extubation, or until successful ICU discharge, or until live hospital discharge, whichever comes first.
Time frame: 14, 21 and 28 days post randomization
Time from randomization to live ICU discharge (up to day 90)
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Time frame: up to 90 days
Time from randomization to live hospital discharge (up to day 90)
Patients will remain in the study and will continue on the assigned ventilation strategy until: successful extubation, successful ICU discharge, live hospital discharge, death, or 90 days post randomization, whichever comes first.
Time frame: up to 90 days
Mortality
Measured as time to death, ICU mortality; hospital mortality; 21, 28, and 90 day mortality
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
SUPPORTIVE_CARE
Masking
NONE
Enrollment
575
Kingston General Hospital
Kingston, Ontario, Canada
London Health Sciences Centre - University Hospital
London, Ontario, Canada
Victoria Hospital
London, Ontario, Canada
Sunnybrook Hospital - Health Sciences Centre
Toronto, Ontario, Canada
North York General Hospital
Toronto, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
UHN- Toronto General Hospital
Toronto, Ontario, Canada
UHN- Toronto Western Hospital
Toronto, Ontario, Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
...and 12 more locations
Time frame: up to 90 days
Weaning Progress
Measured as time from randomization to: first SBT; first successful SBT; first extubation
Time frame: up to 90 days
Weaning Difficulties
Measured as the number of patients failing first SBT or first extubation attempt and requiring up to 7 days to extubate (difficult weaning group/group 2); failing first SBT or first extubation attempt and requiring more than 7 days to extubate (prolonged weaning group/group 3)
Time frame: 90 days
Weaning Complications
Measured as the number of patients: requiring non-invasive ventilation post-extubation; ventilated more than 7 days post randomization, ventilated more than 21 days from time of intubation (prolonged MV group); receiving tracheostomy post-randomization, requiring re-intubation (up to 7d after planned extubation)
Time frame: 90 days
Tolerance of modes
Measured as number of patients ever requiring A/C mode post randomization; number of patient-days requiring A/C mode post randomization
Time frame: 90 days
Serious Adverse Events
Incidence of reported serious adverse events
Time frame: 90 days